Incidence of Hypersensitivity to Cetuximab

Cetuximab is a monoclonal antibody to epidermal growth factor receptor primarily used as adjunctive treatment of metastatic cancers. Hypersensitivity reactions, including anaphylaxis, and especially in the southeastern part of the United States, are one of the most well-known adverse effects of cetuximab. The aim of this meta-analysis is to gain better insight into the overall incidence of cetuximab-induced hypersensitivity reactions. (Source: Journal of Allergy and Clinical Immunology)

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader http://bit.ly/2Stsiak